ArticleDermatology (Basel, Switzerland)2026
Predictors of Super/Poor Omalizumab Response in Chinese Refractory Chronic Spontaneous Urticaria.
Article in Dermatology (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: Omalizumab is an effective treatment for antihistamine-refractory chronic spontaneous urticaria (CSU), although treatment responses vary significantly. While fast and slow responders are well characterized, the profile of super responders (SRs) remains poorly understood. This study aimed to identify clinical and laboratory predictors of super response (SR) and poor/non-response (PR) to omalizumab in refractory CSU.
methodsThis retrospective study analyzed 307 CSU patients treated with omalizumab at a UCARE center between January 2023 and December 2024. SR was defined as achieving Urticaria Activity Score (UAS) = 0 within 1 week and sustained control (UAS7 ≤6, Urticaria Control Test [UCT] >12); PR was defined as UCT <12 after three injections. Demographic, clinical, and laboratory parameters were compared between response groups.
resultsSR patients (n = 138) had lower rates of concomitant chronic inducible urticaria (CIndU) (26.8% vs. 48.5%, p < 0.05), higher total immunoglobulin E (IgE) (113.0 IU/mL), and elevated D-dimer. PR patients (n = 35) were older (median 52.0 years) and had higher angioedema rates (65.5%), lower atopy prevalence (47.1%), higher UAS7 scores, lower IgE (53.5 IU/mL), and higher autologous serum skin test (ASST) positivity (61.5%). Multivariate analysis identified male sex as protective for SR (odds ratio [OR] = 0.556, p = 0.025), while concomitant CIndU predicted non-SR (OR = 2.357, p = 0.001). Predictors of PR included body mass index (BMI) ≥28 kg/m2 (OR = 5.147, p = 0.023), angioedema (OR = 3.309, p = 0.042), and ASST positivity (OR = 4.174, p = 0.011); atopy was protective (OR = 0.299, p = 0.025).
conclusionMale sex and absence of CIndU predict super response to omalizumab, while high BMI, angioedema, and ASST positivity predict poor response. Atopy is associated with better omalizumab response. These findings support personalized treatment strategies in refractory CSU, though further multiethnic validation is warranted. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.